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Introduction {#sec1}
============

The *C. elegans* double-stranded RNA (dsRNA) transporter SID-1 is conserved throughout much of animal evolution, and mammals possess two paralogs, SIDT1 and SIDT2 ([@bib9], [@bib40]). SIDT2 is broadly expressed in mammalian tissue and localizes within late endosomes and lysosomes ([@bib21], [@bib32]). Human and mouse SIDT2 homologs show 95% sequence identity across the entire protein (832 amino acids) and 100% identity at the C-terminal 100 amino acids ([@bib32]). Such a high degree of conservation implies a strongly selected function, and studies have recently emerged that shed light on the role of SIDT2 in mammals.

On the one hand, SIDT2 appears to have retained RNA transporter activity. This was initially suggested by the observation that the ectodomain of SIDT2 binds long dsRNA *in vitro,* similar to *C. elegans* SID-1 ([@bib29]). Consistent with this finding, we subsequently discovered that SIDT2 transports viral dsRNA and that this transport is important for anti-viral immunity ([@bib32]). More specifically, we found that SIDT2 promotes the trafficking of internalized dsRNA across the endolysosomal membrane and into the cytoplasm, where it is recognized by RNA sensors, which in turn promote anti-viral, type I interferon (IFN) signaling. Loss of SIDT2 thus impairs IFN production and survival after viral infection is significantly reduced ([@bib32]). In parallel, SIDT2 has also recently been reported to traffic RNAs *into* the lysosome for degradation in a novel process described as "RNautophagy" ([@bib1]). These experiments---performed using cell-free biochemical assays---suggested that SIDT2 promotes destruction of endogenous RNAs by transporting them from the cytosol into the lysosomes. Such transport would thus be in the opposite direction to that described for viral RNAs, but is potentially consistent with previous observations that RNA transport by *C. elegans* SID-1 is bidirectional and dependent on RNA concentration ([@bib40]).

On the other hand, some studies have observed physiological effects of SIDT2 where the relationship to RNA transport, if any, is unclear. For example, mice lacking SIDT2 demonstrate impaired glucose tolerance, decreased serum insulin levels, and defective insulin secretion ([@bib4], [@bib10], [@bib47]). Two recent studies also demonstrated that *Sidt2*^*−/−*^ mice develop non-alcoholic fatty liver disease ([@bib5], [@bib11]), with one suggesting that this is due to induction of endoplasmic reticulum stress ([@bib11]) and the other proposing that it is the result of defective autophagy ([@bib5]). Finally, work from our group has also demonstrated a potential role for SIDT2 in tumorigenesis ([@bib3]). Specifically, we found that SIDT2 is a transcriptional target of the tumor suppressor p53, that SIDT2 overexpression in *HrasV12;p53*-null mouse embryo fibroblasts impairs cell proliferation, and that small hairpin RNA-mediated knockdown of *Sidt2* in a fibrosarcoma model leads to increased tumor growth following transplantation into immunocompromised *Scid* mice ([@bib3]). Together with the observation that *SIDT2* is transcriptionally downregulated in patient tumors compared with healthy tissue ([@bib2]), these findings thus support a possible tumor suppressive role for SIDT2.

In the current study, we further investigated the role of SIDT2 in tumor development. Unexpectedly, we found that mice lacking SIDT2 display reduced tumor burden and increased survival in both lung adenocarcinoma (LUAD) and intestinal cancer models. Moreover, consistent with its role in dsRNA transport, loss of SIDT2 leads to accumulation of dsRNA, resulting in increased phosphorylation of eIF2α and elevated rates of apoptosis. Our findings therefore suggest that SIDT2, and by extension RNautophagy, play a role in promoting tumor development.

Results {#sec2}
=======

Loss of SIDT2 Inhibits Lung Adenocarcinoma Development {#sec2.1}
------------------------------------------------------

Given the finding that *Sidt2* is a p53 target gene, we sought to investigate its role in tumor suppression *in vivo*. Lung cancer is the leading cause of cancer deaths worldwide, and loss or mutation of *p53* is common in this tumor type. Therefore, we examined the role of Sidt2 in LUAD tumorigenesis by employing an autochthonous mouse model in which mice conditionally express oncogenic *Kras*^*G12D*^ under the control of a lox-STOP-lox element (*Kras*^*LSL-G12D*^). Intratracheal inoculation of adenoviral Cre recombinase excises the STOP cassette, resulting in expression of Kras^G12D^ specifically in lung cells. Kras^G12D^ expression drives development of non-small-cell lung tumors, and loss of p53 promotes tumor progression in this model ([@bib8]). To assess the role of SIDT2 in tumorigenesis in this LUAD model, we crossed *Sidt2*^*−/−*^ mice previously generated in our laboratory ([@bib32]) with *Kras*^*LSL-G12D/+*^ mice and subsequently assessed lung tumor burden in *Kras*^*LSL-G12D/+*^;*Sidt2*^*+/+*^ and *Kras*^*LSL-G12D/+*^;*Sidt2*^*−/−*^ mice 18 weeks after intratracheal adenoviral inoculation. In contrast to our previous report suggesting that SIDT2 has a tumor suppressive role in fibrosarcoma, light microscopic analysis of H&E-stained lung sections showed that *Sidt2*^*−/−*^ animals have reduced tumor burden ([Figure 1](#fig1){ref-type="fig"}A). This was confirmed with subsequent quantification, which showed that mice deficient in SIDT2 developed significantly fewer tumors ([Figure 1](#fig1){ref-type="fig"}B) and had a significant reduction in overall tumor burden ([Figure 1](#fig1){ref-type="fig"}C). Next, we wanted to investigate whether the loss of SIDT2 leads to an impairment of cellular proliferation. To do so, we compared the expression of Ki67, a cellular marker of proliferation, using immunohistochemical staining ([Figure 1](#fig1){ref-type="fig"}D). Consistent with an impairment in cellular proliferation, tumors from *Kras*^*LSL-G12D/+*^;*Sidt2*^*−/−*^ mice had significantly less Ki67-positive cells compared with controls ([Figure 1](#fig1){ref-type="fig"}E). Together, these results thus suggest that SIDT2 facilitates tumor development in the *Kras*^*G12D*^ LUAD model.Figure 1*Kras*^*LSL-G12D/+*^*;Sidt2*^*−/−*^ Mice Have Increased Tumor Burden Compared with Controls(A) Representative images of H&E-stained lung sections from *Kras*^*LSL-G12D/+*^*;Sidt2*^*+/+*^ and *Kras*^*LSL-G12D/+*^*;Sidt2*^*−/−*^ mice 18 weeks following inoculation with 4 × 10^6^ plaque-forming unit adenovirus containing Cre recombinase by intratracheal intubation.(B and C) (B) Average tumor number and (C) tumor burden as a percentage of total lung area was assessed per lung section (n = 19--23 mice per genotype).(D) Representative images of Ki67-stained lung sections of *Kras*^*LSL-G12D/+*^*;Sidt2*^*+/+*^ and *Kras*^*LSL-G12D/+*^*;Sidt2*^*−/−*^ mice.(E) Quantification of average number of Ki67-positive cells per mm^2^ tumor tissue. Analysis was performed on \>25 tumors per mouse (n = mice per genotype).Error bars represent ±SEM. \*p \< 0.05, as calculated by unpaired Student\'s t test.

Loss of SIDT2 Inhibits Growth of *Apc*^*min*^ Intestinal Tumors {#sec2.2}
---------------------------------------------------------------

The difference in the role for SIDT2 in tumorigenesis in the mouse fibrosarcoma and LUAD models prompted us to test another mouse tumor model to examine for context dependency of Sidt2 in cancer. To this end, we chose the well characterized *Apc*^*min*^ mouse model of intestinal cancer. These mice harbor a dominant mutation in the oncogenic *Apc* gene, which leads to spontaneous development of adenomatous polyps, primarily in the distal small intestine (DSI) ([@bib31], [@bib42]).

We subsequently generated *Apc*^*min/+*^ mice lacking *Sidt2* ([Figure S1](#mmc1){ref-type="supplementary-material"}) and monitored the animals over time, sacrificing them after the onset of anemia and/or signs of ill health associated with death in this model (e.g., hunching of the back, weight loss). *Apc*^*min/+*^*;Sidt2*^*−/−*^ mice (median survival: 131 days) survived significantly longer than both *Apc*^*min/+*^;*Sidt2*^*+/+*^ and *Apc*^*min/+*^;*Sidt2*^*+/−*^ mice (median survival: 93 and 99 days, respectively), suggesting that loss of SIDT2 impairs intestinal tumor development ([Figure 2](#fig2){ref-type="fig"}A). To investigate further, *Apc*^*min/+*^;*Sidt2*^*−/−*^ mice were sacrificed at day 100 and appeared to have a lower tumor burden within the DSI compared with *Apc*^*min/+*^;*Sidt2*^*+/+*^ mice ([Figure 2](#fig2){ref-type="fig"}B). To properly assess this, tumor number ([Figures 2](#fig2){ref-type="fig"}C--2E) and tumor area ([Figures 2](#fig2){ref-type="fig"}F--2H) were calculated in the DSI, medial small intestine (MSI), and proximal small intestine (PSI) of 100-day-old *Apc*^*min/+*^;*Sidt2*^*+/+*^ and *Apc*^*min/+*^;*Sidt2*^*−/−*^ mice. There was no difference in tumor number in the colon ([Figure S2](#mmc1){ref-type="supplementary-material"}A) or PSI, whereas *Apc*^*min/+*^;*Sidt2*^*−/−*^ mice had significantly fewer tumors than *Apc*^*min/+*^;*Sidt2*^*+/+*^ mice in the MSI and DSI. Moreover, *Apc*^*min/+*^;*Sidt2*^*−/−*^ mice also had smaller tumors than *Apc*^*min/+*^;*Sidt2*^*+/+*^ mice in the DSI, MSI, and PSI, but again showed no difference in the colon, where tumors are uncommon ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Together, these results suggest that SIDT2 also facilitates tumor development in the *Apc*^*min*^ mouse model of intestinal cancer.Figure 2- *Apc*^*min/+*^*;Sidt2*^*−/−*^ Mice Have Enhanced Survival and Smaller Tumors Compared with Controls(A) Kaplan-Meier survival curve of *Apc*^*min/+*^*;Sidt2*^*+/+*^, *Apc*^*min/+*^*;Sidt2*^*+/−*^, and *Apc*^*min/+*^;*Sidt2*^*−/−*^ mice. Median survival rates of *Apc*^*min/+*^*;Sidt2*^*+/+*^, *Apc*^*min/+*^*;Sidt2*^*+/−*^, and *Apc*^*min/+*^;*Sidt2*^*−/−*^ mice are 93, 99, and 131 days respectively.(B--I) (B) Representative image of distal small intestine of 100-day-old *Apc*^*min/+*^*;Sidt2*^*+/+*^ and *Apc*^*min/+*^;*Sidt2*^*−/−*^ mouse. Total number (C--E) and area (F--H) of visible tumors in the colon and small intestine (distal, medial, and proximal) was quantified in 100-day-old *Apc*^*min/+*^*;Sidt2*^*+/+*^ (n = 12) and *Apc*^*min/+*^*;Sidt2*^*−/−*^ (n = 12) mice.Error bars represent mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 as calculated by unpaired Student\'s t test.See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

As *Apc*^*min/+*^*;Sidt2*^*−/−*^ mice had significantly smaller tumors than *Apc*^*min/+*^*;Sidt2*^*+/+*^ mice across all segments of the small intestine ([Figures 2](#fig2){ref-type="fig"}G--2I), we hypothesized that loss of SIDT2 does not affect tumor initiation, but instead plays a role in the growth of tumors by impairing cell proliferation. To investigate this possibility, we compared the expression of Ki67 in tumors of *Apc*^*min/+*^*;Sidt2*^*−/−*^ and *Apc*^*min/+*^*;Sidt2*^*+/+*^ mice ([Figure 3](#fig3){ref-type="fig"}A). Consistent with the decrease in Ki67-positive cells observed in *Kras*^*LSL-G12D/+*^;*Sidt2*^−/−^ mice, *Apc*^*min/+*^*;Sidt2*^*−/−*^ mice had significantly less Ki67-positive staining overall ([Figure 3](#fig3){ref-type="fig"}B), as well as fewer intratumoral Ki67-positive cells ([Figure 3](#fig3){ref-type="fig"}C) compared with *Apc*^*min/+*^*;Sidt2*^*+/+*^ mice.Figure 3Loss of SIDT2 Impairs Tumor Proliferation(A--C) (A) Representative H&E- and Ki67-stained histological sections of distal small intestine of *Apc*^*min/+*^;*Sidt2*^*+/+*^ and *Apc*^*min/+*^*;Sidt2*^*−/−*^ mice at 100 days of age. Quantification of (B) Ki67-positive staining area as a percentage of total tumor area and (C) average number of Ki67-positive cells per tumor. Analysis was performed on \>20 high-power fields across three mice. Error bars represent mean ± SEM. \*\*\*p \< 0.001 as calculated by unpaired Student\'s t test.

SIDT2 Is Required to Prevent dsRNA Accumulation and PKR/eIF2α Pathway Activation {#sec2.3}
--------------------------------------------------------------------------------

Given the role of SIDT2 in transporting dsRNA across the endolysosomal membrane ([@bib32]), we next assessed the effect of SIDT2 on the subcellular localization of dsRNA within the DSI. To do so, we performed immunofluorescence staining on frozen sections of the DSI of 100-day-old *Apc*^*min/+*^*;Sidt2*^*−/−*^ and *Apc*^*min/+*^*;Sidt2*^*+/+*^ mice using the J2 monoclonal antibody ([Figure 4](#fig4){ref-type="fig"}A), which specifically detects dsRNA helices at least 40 bp in length, in a sequence-independent manner ([@bib39]). Notably, staining for dsRNA was readily observed within the intestinal crypts of *Apc*^*min/+*^*;Sidt2*^*−/−*^ mice but was absent in crypts of *Apc*^*min/+*^*;Sidt2*^*+/+*^ animals and in other parts of the DSI, including tumors ([Figure 4](#fig4){ref-type="fig"}B). To confirm that this was not specific to the *Apc*^*min/+*^ mouse model, we also performed dsRNA staining in lungs of *Kras*^*LSL-G12D/+*^; *Sidt2*^*+/+*^ and *Kras*^*LSL-G12D/+*^; *Sidt2*^*−/−*^ mice using immunohistochemistry ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Consistent with our previous data, we observed a significant increase in cytosolic dsRNA staining in *Kras*^*LSL-G12D/+*^; *Sidt2*^*−/−*^ mice compared with controls ([Figure S3](#mmc1){ref-type="supplementary-material"}B), suggesting that loss of SIDT2 leads to accumulation of dsRNA in the cytosol.Figure 4- Loss of SIDT2 Leads to dsRNA Accumulation within Intestinal Crypts and Increased Phosphorylation of eIF2α(A) Representative image of dsRNA staining of distal small intestine of 100-day-old *Sidt2*^*+/+*^*;Apc*^*min/+*^ and *Sidt2*^*−/−*^*;Apc*^*min/+*^ mice. Arrowheads indicate cells with positive dsRNA staining.(B--D) (B) Quantification of dsRNA-positive stained area per crypt (n = 3--4 mice per genotype). Western blot and densitometry analysis of eIF2α phosphorylation in non-tumor (C) and tumor (D) tissue from distal small intestine of 100-day-old *Sidt2*^*+/+*^*;Apc*^*min/+*^ and *Sidt2*^*−/−*^*;Apc*^*min/+*^ mice normalized to total eIF2α. Each lane corresponds to an individual mouse (n = 4 mice per genotype). Error bars represent mean ± SEM. \*p \< 0.05, \*\*p \< 0.01 as calculated by unpaired Student\'s t test.See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

Cytosolic dsRNAs are bound by RNA-dependent protein kinase (PKR), leading to its autophosphorylation and activation ([@bib12]). Activated PKR subsequently phosphorylates the α subunit of protein synthesis initiation factor eIF2 (eIF2α), resulting in inhibition of protein translation as well as anti-viral and anti-tumor effects ([@bib10], [@bib11]). We therefore wished to determine whether the accumulation of dsRNA in cells deficient in SIDT2 was likely to activate PKR. Although we tested multiple antibodies raised against phosphorylated PKR, none showed an ability to recognize activated murine PKR in control samples via western blot (data not shown), so instead we compared phosphorylation of eIF2α as a proxy for PKR activation. Moreover, because we only observed SIDT2-dependent dsRNA accumulation in the intestinal crypts and not in tumors themselves, we analyzed p-eIF2α expression separately in non-tumor and tumor tissues from the DSI of *Apc*^*min/+*^*;Sidt2*^*−/−*^ and *Apc*^*min/+*^*;Sidt2*^*+/+*^ mice. Notably, *Apc*^*min/+*^*;Sidt2*^*+/+*^ mice displayed higher p-eIF2α levels in non-tumor tissue ([Figure 4](#fig4){ref-type="fig"}C), consistent with dsRNA accumulation and activation of PKR within these cells. This SIDT2-dependent increase in p-eIF2α was less apparent in tumor tissue ([Figure 4](#fig4){ref-type="fig"}D).

In addition to its role in the inhibition of protein translation, PKR activation has been shown to mediate cellular stress responses via regulation of mitogen-activated protein kinases such as c-Jun n-terminal kinase (JNK) ([@bib14], [@bib25], [@bib43]) and promote apoptosis via caspase 8 and nuclear factor-κB ([@bib13]). In line with our hypothesis that PKR activation is increased in the intestinal crypts in the absence of SIDT2, we observed a concurrent increase in phosphorylation of JNK in normal intestinal tissue of *Apc*^*min/+*^*;Sidt2*^*−/−*^ mice compared with *Apc*^*min/+*^*;Sidt2*^*+/+*^ mice ([Figures 5](#fig5){ref-type="fig"}A and 5B). To assess whether loss of SIDT2 leads to increased caspase 8-mediated apoptosis, we assessed and compared cleavage of caspase 8 in the DSI of *Apc*^*min/+*^*;Sidt2*^*−/−*^ and *Apc*^*min/+*^*;Sidt2*^*+/+*^ mice and observed an increase in caspase 8 cleavage products in *Apc*^*min/+*^*;Sidt2*^*−/−*^ normal intestinal tissue ([Figures 5](#fig5){ref-type="fig"}A and 5C). We next performed immunohistochemical staining on intestinal Swiss rolls of *Apc*^*min/+*^*;Sidt2*^*−/−*^ and *Apc*^*min/+*^*;Sidt2*^*+/+*^ mice ([Figure 5](#fig5){ref-type="fig"}D), which revealed an increased number of cleaved-caspase 3-positive cells within intestinal crypts lacking SIDT2 ([Figure 5](#fig5){ref-type="fig"}E). This was further confirmed via TUNEL staining in which *Apc*^*min/+*^*;Sidt2*^*−/−*^ showed increased TUNEL-positive cells within intestinal crypts compared with controls ([Figure 5](#fig5){ref-type="fig"}F). Taken together, these data strongly imply that loss of SIDT2 leads to increased caspase 8- and caspase 3-mediated apoptosis within intestinal crypts, consistent with the restricted tumor growth observed in *Apc*^*min/+*^*;Sidt2*^*−/−*^ animals.Figure 5- *Sidt2*^*−/−*^*;Apc*^*min/+*^ Mice Have Increased Apoptosis in Intestinal Tissue(A--C) (A) Western blot analysis. Phosphorylation of JNK and cleavage of caspase 8 was assessed in normal intestinal tissue of 100-day-old *Sidt2*^*+/+*^;*Apc*^*min/+*^ and *Sidt2*^*−/−*^*;Apc*^*min/+*^ mice. Each lane corresponds to an individual mouse (n = 4 mice per genotype). Densitometry quantification of (B) p-JNK and (C) cleaved caspase 8 normalized to HSP70.(D) Representative images of cleaved caspase 3 staining of distal small intestine of 100-day-old *Sidt2*^*+/+*^*;Apc*^*min/+*^ and *Sidt2*^*−/−*^*;Apc*^*min/+*^ mice.(E) Quantification of dsRNA-positive stained area per crypt (n = 7 mice per genotype).(F) Representative images of TUNEL staining of positive cells from distal small intestine of 100-day-old *Sidt2*^*+/+*^*;Apc*^*min/+*^ and *Sidt2*^*−/−*^*;Apc*^*min/+*^ mice, n = 3 animals per genotype. Arrowheads indicate TUNEL^+^ cells.Error bars represent mean ± SEM. ∗p \< 0.05, ∗∗p \< 0.01 as calculated by unpaired Student\'s t test.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Lower *SIDT2* Expression Is Associated with Improved Survival in Different Human Cancers {#sec2.4}
----------------------------------------------------------------------------------------

Finally, to explore the role of SIDT2 in human cancer, we determined whether different levels of intratumoral *SIDT2* expression are associated with changes in patient survival. Using data collected by The Cancer Genome Atlas Research Network (<http://cancergenome.nih.gov/>) and analyzed via The Pathology Atlas ([@bib44]), we observed that lower intratumoral *SIDT2* RNA levels were associated with significantly improved prognosis in 5 of 17 different cancers (renal, thyroid, gastric, glioma, urothelial) ([Figures 6](#fig6){ref-type="fig"}A--6E). However, consistent with a context-dependent role, intratumoral *SIDT2* RNA levels showed no prognostic significance in 10 other cancers (including LUAD and colon cancer), and lower intratumoral *SIDT2* levels were actually associated with poorer survival in pancreatic and cervical cancers ([Figure S5](#mmc1){ref-type="supplementary-material"}).Figure 6-- Lower SIDT2 Expression Is Associated with Improved Survival in Some Cancers(A--E) Kaplan-Meier curves of overall survival of patients with (A) renal, (B) thyroid, (C) gastric, and (D) urothelial cancer and (E) glioma stratified against *SIDT2* expression from publicly available RNA-seq data. The results shown are in whole based upon data generated by the TCGA Research Network: <http://cancergenome.nih.gov/>.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

In this study, we show that the mammalian SID-1 ortholog SIDT2, which is a transcriptional target for p53, promotes tumor growth. Specifically, loss of SIDT2 in mice caused reduced tumor burden and enhanced survival, with the latter observation supported by data from patients with several different cancers in which lower *SIDT2* expression was associated with an improved prognosis.

Mechanistically, our data from *Apc*^*min*^ animals suggest a model in which the absence of SIDT2 leads to impaired RNautophagy, accumulation of intracellular dsRNA, increased phosphorylation of eIF2α and JNK, and finally, increased apoptosis via activation of caspase 8 ([Figure 7](#fig7){ref-type="fig"}). Notably, when visualized, these changes were only observed in the intestinal crypts and not in tumors themselves, and is potentially in keeping with the strong expression of SIDT2 observed within the crypts of human small intestine ([@bib44]) ([Figure S4](#mmc1){ref-type="supplementary-material"}). Nevertheless, such observations invite the question of how such crypt-related changes could impact subsequent tumor growth. One possible explanation is that the increased apoptosis observed in SIDT2-deficient mice affects cancer stem cells, which reside within the intestinal crypt and play a key role in subsequent tumor growth. Consistent with this, selective depletion of intestinal stem cells has previously been shown to restrict primary tumor growth in mice ([@bib6]), and this would be in keeping with our observation that SIDT2-deficient tumors show reduced proliferation ([Figure 3](#fig3){ref-type="fig"}). Another possible explanation is that increased eIF2α activation in the absence of SIDT2 induces differentiation (and thus loss) of these same intestinal stem cells, as has been observed by others ([@bib18]). Further work to investigate the specific effects of SIDT2 on cancer stem cell development will hopefully shed light on these possibilities.Figure 7Loss of SIDT2-Mediated RNAutophagy Leads to Increased Apoptosis and Cell ProliferationSIDT2 is a dsRNA transporter that mediates the lysosomal degradation of cellular RNAs via RNAutophagy. Loss of SIDT2 leads to accumulation of cellular RNA within the cytosol. Binding of these RNAs by protein kinase RNA-activated (PKR) leads to its activation and subsequent phosphorylation of eukaryotic translation initiation factor 2 alpha (eIF2α). Phosphorylation of eIF2α leads to inhibition of protein translation and cell proliferation, as well as induction of apoptosis.

Notwithstanding our inability to activate PKR (see below), PKR seems a likely candidate in mediating the downstream effects in our *Apc*^*min*^ *Sidt2*^*−/−*^ mice. After all, PKR has well-established roles not only in binding and responding to intracellular dsRNA but also in inducing eIF2α phosphorylation, JNK activation, and caspase 8-mediated activation of caspase 3 to induce apoptosis. Consistent with our results, PKR expression and auto-phosphorylation have previously been reported to be increased in multiple human malignancies, including colon and lung cancer ([@bib23], [@bib24]), and those with higher p-PKR and p-eIF2α had significantly longer survival ([@bib15], [@bib17], [@bib35]).

Given the presence of intracellular dsRNA in *Apc*^*min*^;*Sidt2*^*−/−*^ intestinal crypts, we also assessed whether there was induction of a type I IFN response in these tissues. However, we were unable to detect upregulation of *Ifnβ* or various IFN-stimulated genes in tissues of *Apc*^*min/+*^*;Sidt2*^*−/−*^ mice (data not shown), suggesting that the reduced tumor burden observed in SIDT2-deficient mice is unlikely to be due to the anti-tumor effects of type I IFN ([@bib7]). This lack of a type I IFN response may also provide a clue as to the nature of the dsRNA that accumulates in the absence of SIDT2. Specifically, the type I IFN response to cytoplasmic dsRNA is mainly orchestrated by the RIG-I-like receptors, RIG-I and MDA-5 ([@bib27], [@bib45]). RIG-I specifically recognizes short dsRNA and ssRNA with 5′ triphosphate ends ([@bib19]), a common feature of viral RNAs, and MDA-5 is critical for the detection of long dsRNAs (\>1,000 bp) ([@bib22], [@bib36], [@bib37]). The lack of a detectable type I IFN response in *Apc*^*min/+*^*;Sidt2*^*−/−*^ mice therefore suggests that the dsRNAs that accumulate in the intestinal crypts of these animals do not possess 5′triphosphate ends and are not long enough to activate MDA-5. In contrast, PKR requires a minimum dsRNA region of only 30 bp ([@bib28], [@bib30]) and can recognize RNAs with limited stem loop or duplex structures ([@bib34]), including small interfering RNA ([@bib38], [@bib41]), small nucleolar RNA ([@bib46]), and bacterial RNAs ([@bib20]). Indeed, PKR has recently been reported to bind endogenous nuclear dsRNAs during cell mitosis ([@bib25]), noncoding Alu RNA and mitochondrial RNAs that are capable of forming intramolecular dsRNA structures ([@bib26]). These RNA species may therefore be more likely to accumulate in the absence of SIDT2. At the same time, it has been proposed that autophagy is important for the degradation of many types of cytosolic RNAs, including retrotransposon, viral, and cellular messenger RNAs ([@bib1], [@bib16], [@bib33]), so impaired lysosomal degradation of RNA in the absence of SIDT2 could also lead to accumulation of these RNAs within the intestinal crypt. Future studies to identify the RNA cargo of SIDT2 within the intestine will clarify these possibilities.

Finally, it should be noted that the apparent protective effect of lower intratumoral *SIDT2* levels on patient survival was limited to certain types of cancers. Moreover, in pancreatic and cervical cancers, lower intratumoral *SIDT2* levels were associated with poorer survival. Thus, the role of SIDT2 in promoting tumor growth may only apply in specific contexts, and this may explain the apparent contradiction between the data described here and our earlier findings, namely, that SIDT2 functions as a tumor suppressor in a fibrosarcoma model ([@bib3]). Regardless, the results from this study identify a role for SIDT2 and RNautophagy in promoting cancer development *in vivo* and suggest the possibility that strategies to inhibit SIDT2 and/or RNautophagy could be a useful adjunct to existing treatment for certain types of cancer.

Limitations of Study {#sec3.1}
--------------------

In this study, we were unable to directly show that the accumulation of dsRNA in *Sidt2*^*−/−*^ mice leads to increased PKR activation. This was despite trying a range of different approaches, including commercial antibodies designed to detect phosphorylated murine PKR, phos-tag gels, and direct mass spectrometry methods. Reliable detection of murine phospho-PKR is a problem that is well recognized in the field, and future studies using *Sidt2*^*−/−*^*;Pkr*^*−/−*^ animals may shed further light on the mechanistic interplay between these two proteins in cancer development.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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